AngioDynamics (NASDAQ:ANGO) Hits New 52-Week High – Should You Buy?

Posted by Brian Himes on Sep 1st, 2026

AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $16.29 and last traded at $16.00, with a volume of 7297 shares. The stock had previously closed at $16.13.

Wall Street Analyst Weigh In

Several brokerages have commented on ANGO. Canaccord Genuity Group raised their price target on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. HC Wainwright increased their price objective on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Zacks Research lowered AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Finally, Wall Street Zen upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, AngioDynamics has a consensus rating of “Hold” and an average target price of $19.50.

View Our Latest Research Report on ANGO

AngioDynamics Stock Performance

The company has a market cap of $657.11 million, a P/E ratio of -18.22 and a beta of 0.33. The business has a 50 day moving average price of $14.41 and a two-hundred day moving average price of $12.29.

AngioDynamics (NASDAQ:ANGO – Get Free Report) last posted its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.04. The business had revenue of $86.61 million for the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. As a group, research analysts expect that AngioDynamics, Inc. will post -0.25 EPS for the current year.

Insider Buying and Selling at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the transaction, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.00% of the company’s stock.

Institutional Investors Weigh In On AngioDynamics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ANGO. Farther Finance Advisors LLC boosted its position in AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 1,199 shares during the period. Kemnay Advisory Services Inc. purchased a new position in shares of AngioDynamics in the fourth quarter valued at about $27,000. State of Wyoming purchased a new position in shares of AngioDynamics in the second quarter valued at about $31,000. Legal & General Group Plc bought a new position in shares of AngioDynamics during the second quarter valued at about $45,000. Finally, Russell Investments Group Ltd. boosted its holdings in shares of AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after purchasing an additional 3,213 shares during the period. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Company Profile

(Get Free Report)

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.